• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Foghorn Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    7/1/25 4:40:46 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FHTX alert in real time by email
    fhtx-20250627
    false000182246200018224622025-06-272025-06-27

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ________________________
    FORM 8-K
    ________________________________________________________________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): June 27, 2025
    ________________________________________________________________________________________________
    Foghorn Therapeutics Inc.
    (Exact name of registrant as specified in its charter)
    ________________________________________________________________________________________________
    Delaware 001-39634 47-5271393
    (State or other jurisdiction of incorporation) 
    (Commission
    File Number)
     (IRS Employer Identification No.)
    500 Technology Square, Ste 700
    Cambridge,
    MA
    02139
    (Address of principal executive offices)(Zip Code)
    (Registrant’s telephone number, including area code): (617) 586-3100
    Not Applicable
    (Former name or former address, if changed since last report)
    ________________________________________________________________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class 
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, $0.0001 par value per share FHTX The Nasdaq Global Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 1.01     Entry into a Material Definitive Agreement.
    On June 27, 2025, Foghorn Therapeutics Inc. (the “Company”) entered into a lease agreement (the “Lease”) with ARE-MA Region No. 77, LLC (the “Landlord”) for the lease of 72,846 square feet of space located at 99 Coolidge Avenue, Watertown, MA 02472, (the “Premises”) for the Company’s principal executive offices and for research, development, manufacturing, and related uses. The commencement date of the Lease is July 16, 2025. Base rent accrues nine and one-half (9½) months after the earlier of (i) the date the Landlord delivers the entire Premises to the Company and (ii) the date the Landlord could have delivered the entire Premises but for delays caused by the Company (the “Rent Commencement Date”), which is anticipated to be October 1, 2026. The Lease will expire 108 months from the first day of the first full month of the Rent Commencement Date, unless terminated earlier (the “Initial Term”).

    The annual base rent under the Lease will initially be abated to $3.9 million based on 45,000 rentable square feet for the first year following the Rent Commencement Date and approximately $5.2 million for the following year based on 60,000 rentable square feet. Thereafter, the rent will be approximately $6.3 million and, starting on October 1, 2027, will be subject to a 3% annual increase for each remaining year of the Initial Term. The Company will also be responsible for a pro rata share of the payment of additional rent to cover the Company’s share of the annual operating and tax expenses for the Premises, with the Company’s share estimated to be approximately 22.71%. The Company holds two (2) successive options to extend the term for additional periods of five (5) years each, exercisable by written notice delivered not less than twelve (12) months and not more than eighteen (18) months prior to the expiration of the then-current term and subject to customary conditions, including that no default then exists.

    The foregoing description of the Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

    Item 1.02     Termination of a Material Definitive Agreement.
    On June 27, 2025, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the “Lease Termination Agreement”) with ARE-Tech Square, LLC (the “Prior Landlord”) to terminate that certain lease agreement, dated as of October 23, 2019, as amended, (the “Prior Lease”) for approximately 81,441 rentable square feet at 500 Technology Square, Cambridge, Massachusetts (the “Prior Premises”). The Lease Termination Agreement provides for the early termination of the Prior Lease, which was originally scheduled to expire on September 30, 2028. Under the Lease Termination Agreement, the Company is required to pay all rent and other amounts due under the Prior Lease through the applicable termination date.

    The foregoing description of the Lease Termination Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Lease Termination Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.

    Item 9.01    Financial Statements and Exhibits.
    (d) Exhibits

    Exhibit No.Description
    10.1
    Lease Agreement, by and between Foghorn Therapeutics Inc. and ARE-MA Region No. 77, LLC, dated June 27, 2025
    10.2
    Lease Termination Agreement and Voluntary Surrender of Premises, by and between Foghorn Therapeutics Inc. and ARE-Tech Square, LLC, dated June 27, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    FOGHORN THERAPEUTICS INC.
     
    By: /s/ Kristian Humer
     Kristian Humer
     Chief Financial Officer
    Date: July 1, 2025

    Get the next $FHTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FHTX

    DatePrice TargetRatingAnalyst
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    1/30/2025$10.00Buy
    B. Riley Securities
    9/3/2024$18.00Buy
    Jefferies
    8/19/2024$20.00Outperform
    Evercore ISI
    3/28/2023$10.00Buy
    BofA Securities
    1/5/2023$20.00Outperform
    BMO Capital Markets
    12/15/2021$23.00 → $26.00Overweight
    Morgan Stanley
    11/22/2021$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $FHTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Smith Ian F

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:29:40 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Parshall B Lynne

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:29:16 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mendelsohn Michael

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:28:43 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

      Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

      4/23/25 8:16:18 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Foghorn Therapeutics with a new price target

      B. Riley Securities initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $10.00

      1/30/25 7:55:02 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Foghorn Therapeutics with a new price target

      Jefferies initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $18.00

      9/3/24 7:47:52 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

      Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

      7/1/25 6:30:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseas

      5/22/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

      FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $220.6 million as of March 31, 2025, provides cash runway into 2027 CAMBRIDGE, Mass., May 14, 20

      5/14/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    SEC Filings

    See more
    • Foghorn Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

      7/1/25 4:40:46 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Foghorn Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

      6/17/25 4:01:55 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Foghorn Therapeutics Inc.

      10-Q - Foghorn Therapeutics Inc. (0001822462) (Filer)

      5/14/25 7:07:10 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

      5/1/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $FHTX
    Financials

    Live finance-specific insights

    See more
    • Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

      First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust preclinical monotherapy anti-tumor activity for both selective CBP and selective EP300 degrader programs Progress with FHD-909, selective CBP, and selective EP300 degrader programs further validates Foghorn's drug discovery engine Conference call and webcast today at 5 pm ET / 2 pm PT CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseas

      4/9/24 4:30:00 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

      Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, inclu

      3/26/24 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Foghorn Therapeutics Inc.

      SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

      10/8/24 5:44:34 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Foghorn Therapeutics Inc.

      SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)

      9/20/24 6:00:44 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Foghorn Therapeutics Inc. (Amendment)

      SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

      6/10/24 9:48:22 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care